PMID- 38128817
OWN - NLM
STAT- MEDLINE
DCOM- 20240115
LR  - 20240115
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 553
DP  - 2024 Jan 15
TI  - Clinical value of serum MMP-3 in chronic kidney disease.
PG  - 117725
LID - S0009-8981(23)00527-2 [pii]
LID - 10.1016/j.cca.2023.117725 [doi]
AB  - BACKGROUND: Chronic kidney disease (CKD) is defined as the progressive 
      deterioration of renal parenchyma and decline in renal unit function. In the 
      early stages of CKD(G1 + G2), symptoms are usually not obvious and cannot be 
      effectively recognized on the basis of available clinical markers. Progression to 
      the middle and late stages of CKD results in severe kidney damage with multiple 
      complications causing adverse outcomes, including death. Therefore, the early 
      diagnosis and monitoring of CKD is critical. Matrix metalloproteinase-3 (MMP-3), 
      an extracellular matrix-degrading enzyme, plays an important role in kidney 
      diseases. However, the clinical significance of serum MMP-3 levels in CKD has 
      rarely been reported. METHODS: We quantified the serum MMP-3 levels of 237 
      patients with CKD and 96 healthy individuals by using a highly sensitive 
      time-resolved fluorescence immunoassay and analyzed differences in MMP-3 levels 
      among the stages of CKD and the correlations of these changes with clinical 
      indicators. RESULTS: The serum MMP-3 concentrations of patients with CKD 
      (171.76 +/- 165.22 ng/mL) were significantly higher than those of healthy controls 
      (34.05 +/- 22.93 ng/mL; P < 0.0001). In CKD, serum MMP-3 levels were significantly 
      correlated with estimated glomerular filtration rate (eGFR) (r =  - 0.5804, 
      P < 0.0001), serum creatinine (CREA) (r = 0.5823, P < 0.0001), blood urea 
      nitrogen (BUN) (r = 0.6106, P < 0.0001), and protein-to-creatinine ratio 
      (r = 0.4992, P < 0.0001). Randomized forest analysis finds CREA, BUN, and MMP-3 
      most significant influences on CKD disease severity. The critical value of MMP-3 
      concentration of 40.39 ng/mL combined with eGFR was effective in diagnosing 
      positive patients in the early (G1 + G2) stage of CKD and showed a positivity 
      rate of 73.45 %. Moreover, in the early stages of CKD, patients with CKD who had 
      serum MMP-3 concentration > 100 ng/mL had more severe renal impairment and 
      inflammation than those with CKD who have lower serum MMP-3 concentrations. 
      CONCLUSION: Elevated serum MMP-3 levels are correlated with decreased kidney 
      function in CKD progression, and patients with concomitant inflammation may 
      express high levels of serum MMP-3. Serum MMP-3 may assist eGFR in improving the 
      diagnosis of patients with early CKD.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Fu, Yulin
AU  - Fu Y
AD  - College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 
      China.
FAU - Song, Cheng
AU  - Song C
AD  - The Taihu Sanatorium of Jiangsu Province (The Taihu Rehabilitation Hospital of 
      Jiangsu Province), Wuxi, Jiangsu 214086, China.
FAU - Qin, Yuan
AU  - Qin Y
AD  - College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 
      China.
FAU - Zheng, Tianyu
AU  - Zheng T
AD  - College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 
      China.
FAU - Zhou, Xiumei
AU  - Zhou X
AD  - College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 
      China.
FAU - Zhao, Xueqin
AU  - Zhao X
AD  - College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 
      China.
FAU - Zou, Jian
AU  - Zou J
AD  - Department of Laboratory Medicine, The Affiliated Wuxi People's Hospital of 
      Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing 
      Medical University, Wuxi, Jiangsu 214023, China.
FAU - Huang, Biao
AU  - Huang B
AD  - College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 
      China. Electronic address: jswxhb@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231219
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Humans
MH  - *Matrix Metalloproteinase 3
MH  - *Renal Insufficiency, Chronic
MH  - Kidney
MH  - Glomerular Filtration Rate
MH  - Inflammation
MH  - Creatinine
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Diagnosis
OT  - Kidney function
OT  - Matrix metalloproteinase-3
OT  - Stage
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/22 00:42
MHDA- 2024/01/15 12:43
CRDT- 2023/12/21 19:28
PHST- 2023/09/02 00:00 [received]
PHST- 2023/11/26 00:00 [revised]
PHST- 2023/12/14 00:00 [accepted]
PHST- 2024/01/15 12:43 [medline]
PHST- 2023/12/22 00:42 [pubmed]
PHST- 2023/12/21 19:28 [entrez]
AID - S0009-8981(23)00527-2 [pii]
AID - 10.1016/j.cca.2023.117725 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2024 Jan 15;553:117725. doi: 10.1016/j.cca.2023.117725. Epub 2023 
      Dec 19.